EARLY IMMUNIZATION OF NEONATES WITH TRIVALENT ORAL POLIOVIRUS VACCINE by Weckx, Lily Yin et al.
Early immunization of neonates with trivalent
oral poliovirus vaccine*
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Described is the evaluation in Brazil of the immune response of early immunization with trivalent oral
poliovirus vaccine (TOPV). A total of 85 normal neonates from Sao Paulo were assigned one of the fol-
lowing immunization schedules: group A - one dose of TOPV at birth and subsequent doses at 2, 4,
and 9 months of age; or group B - one dose of TOPV at 2, 4 and 6 months of age. Blood samples
were collected sequentially from the mother at delivery, from the umbilical cord, and from the child at 2,
4, 6, 9 and 12 months of age for assay of poliovirus neutralizing antibodies. Administration of TOPV at
birth, in addition to establishing immunity against poliomyelitis at an earlier stage, produced a superior
immune response to poliovirus type 3. At the end of the first year, the proportion of susceptible indivi-
duals was 3.7% in group A and 25.9% in group B. When immunization against poliomyelitis is started at
birth, excellent seroconversion rates are obtained from the third dose onward.
Introduction
Immunization of neonates with oral poliovirus vacci-
ne (OPV) was studied extensively in the 1950s and
1960s (1-10). Recently, this possibility has been re-
evaluated, because in developing countries, where
poliomyelitis is not yet under control, early vaccina-
tion would permit immunization at a time when there
is little interference from intestinal organisms and
ensure the administration of at least one dose while
the child is still under medical care. In Sao Paulo,
Brazil, more than 90% of deliveries occur in hospi-
tals. Also, the occurrence in very young childrena of
poliomyelitis that is associated with an immunity gap
(11) would be prevented by earlier establishment of
immunity against the disease. Recently, studies car-
ried out in China (12) and in India (13) have reported
excellent rates of seroconversion after early adminis-
tration of poliovirus vaccine, with higher antibody
titres during the first months of life (12,14).
On the basis of these data WHO now recom-
mends a supplementary dose of polio vaccine at
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birth, in addition to the three doses for primary
immunization (15,16). We therefore carried out a
study to assess the immunological response to early
poliomyelitis vaccination of neonates in Sao Paulo.
Materials and methods
The protocol was approved by the Committee of
Ethical Control of Clinical Research, Escola Paulista
de Medicina, Sao Paulo.
Study population
A total of 85 children from Sao Paulo were evaluated
from March 1986 to September 1988. The children
satisfied the following criteria: they were normal
full-term newborn infants, had a birth weight of over
2500g, and a 5-minutes Apgar score of >7. In addi-
tion, their mothers had normal pregnancies, without
infectious episodes, and amniorrhexis less than 12
hours before delivery. After obtaining the written
consent of one of the parents, the neonates were assi-
gned at random to one of two groups (A and B), each
of which received different poliomyelitis immuniza-
tion schedules. All children were followed up in the
nursery and afterwards at monthly visits throughout
the first year of life. Those who received an extra
dose of vaccine as a result of immunization campai-
gns were excluded from the study. Of the 85 neo-
nates at the beginning of the study, only 54 (27 in
each group) followed the protocol until the end.
Immunization schedules
Trivalent oral poliovirus vaccine (TOPV;
SmithKline), which was distributed by the Ministry
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of Health, was used for both study groups; however,
because the composition of the vaccine was modified
during the study period, group B children received a
higher concentration of vaccine to poliovirus type 3.
The schedules and composition of vaccine used with
the two study groups are shown below.
- Group A: TOPV was given at birth (second day
of life) and subsequently at 2, 4, and 9 months of
age. Composition of vaccine: poliovirus type 1
(PI) = 1 million TCID50; type 2 (P2) = 100 000
TCID50; and type 3 (P = 300 000 TCID50.
- Group B: TOPV was given according to the offi-
cial schedule established in Brazil, i.e., at 2, 4
and 6 months of age. Composition of vaccine:
P1 = 1 million TCID50; P2 = 100 000 TCID50; and
P3 = 500 000 TCID50.
Laboratory tests
In each case blood samples were collected from the
mother at delivery, from the umbilical cord, and
from the child, by venepuncture, at 2, 4, 6, 9 and 12
months of age. Sera, which were obtained by centri-
fugation of the blood samples, were stored at -20 °C
until being analysed. The levels of types 1, 2 and 3
poliovirus antibodies were assayed by the neutraliza-
tion technique (17) at dilutions of between 1:5 and
1:10 240.
Evaluation parameters
Individuals whose poliovirus neutralizing antibody
titres were .1:5 were considered to be seropositive
(11, 18, 19). Seroconversion was taken to be de-
velopment of poliovirus neutralizing antibodies in
previously seronegative individuals or at least a four-
fold increase in the expected titre caused by a reduc-
tion in transplacental antibodies. A maternal anti-
body half-life of 30 days was assumed for this
purpose (16).
Statistical analysis
Because of our sample characteristics, the following
nonparametric methods were used in the statistical
analysis of the results: Wilcoxon's, Friedman's and
Cochran's G tests; the level of significance was 0.05
(5%). For calculation of the geometric mean anti-
body titres (GMT), titres <1:5 were taken to be equal
to 1:2.5 and those >1:10 240 to be 1:20 480 (20).
Results
With the exception of one child, poliovirus neutrali-
zing antibodies were present in all the children at
birth; the antibody levels were lower in the umbilical
cord (GMT: P, = 109.49; P2 = 71.77; and P3 =
46.88) than in maternal blood (GMT: P1 = 130.03;
P2 = 100.45; and P3 = 73.87). The difference was sig-
nificant for P2.
Sequential determination of poliovirus anti-
bodies in a given child throughout the first year of
life permits evaluation of the serological response to
the vaccine. The results obtained were analysed for
antibody level, seropositivity, susceptibility and sero-
conversion.
Antibody level
For group A children (who received TOPV at birth)
a slight decrease in the antibody titres to P1 and P3
occurred between birth and the second month of life,
but increased thereafter (Fig. 1). In general there
was a good serological response to this vaccination
schedule, leading at the end of the first year to high
antibody titres against the three polioviruses.
For group B children (who were immunized first
at the age of 2 months) the antibody levels for the
three polioviruses decreased significantly until the
second month. This was due to the natural loss of
maternal antibodies present at birth. The reduction in
antibodies to P3 was more pronounced, with the
increase in titres occurring only from the fourth
month onward. At the end of the first year the mean
titres for P2 (557.22) and P1 (153.03) were consider-
ably greater than the mean for P3 (40.02).
Seropositivity
In group A the percentage seropositivity (titre >1:5)
for P1 and P2 was rather high and constant during the
first year of life. The seropositivity for P3 decreased
in the second month, but recovered subsequently,
and by the end of the primary immunization sched-
ule, the protection rates against the three polioviruses
were excellent (Fig. 2) (Pi=100%, P2=100%,
and P3=96.3%).
In group B, although the seropositivity for P,
and P2 remained high, there was a significant decrea-
se in that for P3 until the fourth month (minimum
seropositivity, 51.9%). At the end of the first year,
while high seropositivity rates were obtained for Pi
and P2, only 74.1% of the children were protected
against poliovirus P3.
Susceptibility
Individuals who are susceptible to one, two, or three
types of poliovirus were classifled as singly, doubly
or triply susceptible, respectively. Almost all suscep-
tible individuals in group A were singly susceptible,
while in group B there were a considerable number
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Fig. 1. Geometric mean titres (reciprocal) for poliovirus neutralizing antibodies in group A and group B children;
P1 = poliovirus type 1; P2 = poliovirus type 2; P3 = poliovirus type 3.
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Cord 2 months 4 months 6 months 9 months 12 months
P1 86.45 63.13 145.72 180.08 123.06 205.63 P1 138.69 33.66 102.17 152.44 152.73 153.03
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Fig. 2. Percentage of seropositive individuals (antibody titre >1:5) for poliovirus in group A and group B; P1 = polio-
virus type 1; P2 = poliovirus type 2; P3 = poliovirus type 3.
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of doubly susceptible individuals, in addition to a
higher overall proportion of susceptible individuals.
In group A, the proportion of susceptibles aged 2-6
months was particularly low. At the end of the two
schedules the proportion of susceptible individuals in
group A was 3.7%, while in group B it was 25.9%
(Fig. 3).
Seroconversion
Seroconversion, an important parameter in evalua-
ting the active response to a vaccine, was determined
by assaying the antibody levels in both groups two
months after each dose of vaccine had been adminis-
tered (Fig. 4).
For children in group A, seroconversion increa-
sed progressively with each successive dose. After
three doses (including dose zero given at birth, the
rate of seroconversion for the three polioviruses was
high (PI = 92.6%, P2 = 96.3%, P3 = 92.6%), and
close to that obtained after four doses (dose 3) (P1 =
100%, P2 = 100%, P3 = 96.3%).
High rates of seroconversion for P1 (96.3%) and
P2 (100%) were obtained for children in group B;
however, only 74.1% of these children had sero-
converted to the P3 vaccine virus by the end of the
schedule.
Discussion
One of the problems associated with early immuni-
zation with TOPV is the possible interference of
maternal antibodies with the response to the adminis-
tered vaccine (1-6, 12). In the present study, passive-
ly transferred maternal antibodies were present in all
but one neonate and did not seem to have influenced
the final outcome, since almost all children in group
A seroconverted. Dong et al. have shown that the
seroconversion is delayed when high levels of mater-
nal antibodies are present at birth (12); in contrast,
we found this outcome only for P1. Because of the
small number of patients in our study, the evaluation
for other poliovirus types was difficult. The high
gastric acidity during the first 24 hours of life
(21,22) and the presence of ingested amniotic fluid
(23) could theoretically interfere with vaccines given
immediately after birth; the children were therefore
vaccinated on their second day of life. Also, the chil-
dren in our study were routinely breast-fed.
Administration of a supplementary dose of
TOPV at birth led to a higher level of polio antibo-
dies during the first months of life (Fig. 1), with a
greater seropositivity (Fig. 2), and consequently to a
decrease in the proportion of susceptible individuals
over this period (Fig. 3). Use of a supplementary
dose at birth led also to increased protection at the
end of the primary immunization schedule: only
Fig. 3. Percentage of susceptible individuals (antibody titre <1:5) for poliovirus in group A and group B: single =
susceptible to one poliovirus type; double = susceptible to two poliovirus types; total = all susceptibles.
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Fig. 4. Percentage seroconversion to poliovirus types after each dose of vaccine. Seroconversion was defined as the
development of antibodies in formerly seronegative individuals or a .4-fold increase in the level of a type-specific antibody.
Assays were performed 2 months after administration of each dose of vaccine. P1 = poliovirus type 1; P2 = poliovirus type
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3.7% of susceptible individuals were in group A,
compared with 25.9% in group B, whose schedule
began in the second month of life. How can the
improved serological response in children who
receive TOPV at birth be explained? Why were the
same results not observed in 2-month-old children
who had already developed immunological mechan-
isms, were subject to little interference from maternal
antibodies, and who had received a more concen-
trated vaccine?
In India, John obtained excellent rates of sero-
conversion in children who received their first dose
of poliovirus vaccine during the first week of life,
the rates being slightly higher than those resulting
from administration of the vaccine at 5 or 6 weeks of
age (13). In Brazil, Neves et al. have reported better
rates of seroconversion when administration of
TOPV is started in the first rather than in the third
month of life (24). It should be noted that these two
studies were performed in tropical countries, where
the efficacy of the routinely administered oral polio-
vaccine is lower than that in countries with tempera-
te climates (25, 26). Several factors play a role in
accounting for these differences: potency is reduced
in tropical countries because of deficiencies in the
storage of the vaccine (27); there could be diffe-
rences in inhibitory factors in the digestive tract that
have an effect on the implantation and replication of
the vaccine virus (28); and the interference by other
enteroviruses in small children in tropical countries
may reduce the immune response (29-32). The inci-
dence of enterovirus infections among neonates in
Brazil (33) and elsewhere (34) is significantly
lower than that among older children, and may ac-
count for the better seroconversion rates observed in
younger children. Our results indicate that there is
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an improved serological response to TOPV when
the schedule is started early, during the neonatal per-
iod, particularly as far as poliovirus type 3 is con-
cerned.
During the outbreak of poliomyelitis in north-
east Brazil in 1986, most cases were due to polio-
virus type 3. Epidemiological investigations have
revealed that the TOPV used to immunize the chil-
dren has a low efficacy, particularly in terms of the
P3 component. Higher seroconversion rates were
obtained by doubling the P3 level (35), and this led
the Brazilian Ministry of Health to modify the com-
position of the vaccine used, increasing the P3 level
from 300 000 TCID50 per dose to 500 000 TCID50
per dose.
The children in group B in our study who re-
ceived their first dose of TOPV in their second
month of life, were immunized from the beginning
with a vaccine that had the higher P3 level. Even so,
the rate of seroconversion to P3 was lower than that
of children who received their first dose at birth
using vaccine with a P3 level of 300 000 TCID50 per
dose. This indicates that immunization of neonates
with TOPV may be a much more relevant factor
than use of a higher vaccine concentration.
With the official schedule, beginning in the
second month of life, primary immunization with
three doses of TOPV resulted in about 25% of the
children remaining incompletely immunized, and
susceptible to poliovirus type 3. In the case of expo-
sure to wild poliovirus this proportion of the popula-
tion can be considered to be at risk. In contrast, with
early immunization, better protection can be
achieved and the risk may diminish considerably.
When a supplementary dose of TOPV is given
at birth (zero dose), excellent rates of seroconversion
for the three poliovirus types are produced from the
third dose onward, and after the fourth dose, the
seroconversion rates are still slightly higher (Fig. 4).
No difficulty was experienced in administering
the TOPV to neonates. The schedule is feasible
operationally and requires no specialized technical
knowledge or additional equipment. In view of the
results obtained, we propose that immunization
against poliomyelitis be initiated early in the neona-
tal period; every newborn can receive the first dose
of polio vaccine before being discharged from hospi-
tal. This measure together with other efforts to
improve vaccination will contribute considerably to
the control of poliomyelitis.
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Resume
Vaccination precoce des nouveau-n6s par
le vaccin antipoliomyelitique buccal
trivalent
La vaccination des nouveau-nes contre la polio-
myelite offre certains avantages; par exemple,
l'enfant recoit la premiere dose de vaccin lorsqu'il
est encore a I'hopital, a un age ou il y a peu
d'interference avec les germes enteriques et, sur-
tout, cela permet d'assurer une protection precoce
contre la maladie.
Nous avons effectu6 une 6tude visant a quan-
tifier la r6ponse immunitaire a une vaccination
antipoliomyelitique pr6coce avec un vaccin buccal
trivalent (VPOT) a Sao Paulo, au Bresil. Au total,
85 nouveau-nes normaux ont forme la population
d'6tude, qui a 6te divisee au hasard en deux
groupes soumis a differents calendriers vaccinaux:
groupe A - une dose de VPOT a la naissance puis
a 2, 4 et 9 mois; groupe B - une dose de VPOT a
2, 4 et 6 mois. Dans chaque cas, on a effectu6
des pr6levements sanguins au moment de l'accou-
chement chez la mere et au cordon ombilical, puis
chez l'enfant a 2, 4, 6, 9 et 12 mois. On a ainsi
obtenu une evaluation s6quentielle de l'immunit6
antipoliomyelitique au cours de la premiere annee.
On a titr6 les anticorps des trois souches de polio-
virus par neutralisation.
L'administration d'une dose suppl6mentaire de
VPOT a la naissance, outre qu'elle etablit l'immu-
nite antipoliomyelitique a un age plus precoce,
produit egalement une meilleure reponse immuni-
taire contre le P3. A la fin de la premiere annee, la
proportion de sujets sensibles etait de 3,7% dans
le groupe A et de 25,9% dans le groupe B. La
faible incidence des infections enterovirales chez
le nouveau-n6 a peut-etre contribu6 a cette
meilleure r6ponse immunitaire. Lorsqu'on com-
mence la vaccination antipoliomyelitique des la
naissance, on obtient d'excellents taux de sero-
conversion a partir de la deuxieme dose c'est-a-
dire a 4 mois.
Notre calendrier vaccinal est tout a fait appli-
cable et chaque enfant a requ sa premiere dose
de vaccin avant sa sortie de l'h6pital. Cette facon
de proceder devrait se g6neraliser, en particulier
dans les pays ou cette maladie s6vit encore.
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